Cited 0 time in
NRF2 activation in cancer and overview of NRF2 small molecule inhibitors
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Ngo, Hoang Hai | - |
| dc.contributor.author | Yu, Bo-Yeong | - |
| dc.contributor.author | Lee, Jeong-Eun | - |
| dc.contributor.author | Kim, Hyunwoo | - |
| dc.contributor.author | Keum, Young-Sam | - |
| dc.date.accessioned | 2025-08-25T04:30:16Z | - |
| dc.date.available | 2025-08-25T04:30:16Z | - |
| dc.date.issued | 2025-08 | - |
| dc.identifier.issn | 0253-6269 | - |
| dc.identifier.issn | 1976-3786 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/58989 | - |
| dc.description.abstract | NRF2 is a redox-sensitive transcription factor that activates the expression of phase II detoxifying and antioxidant enzymes. In addition to maintaining redox homeostasis, NRF2 regulates various other processes, including metabolism, stem cell renewal, mitochondrial function, and proteostasis. NRF2 is considered a tumor suppressor because its activation by chemopreventive phytochemicals contributes to the detoxification of oxidants and electrophiles in normal cells. However, aberrant NRF2 activation occurs in cancer due to mutations in the KEAP1/NRF2 pathway, and it contributes to the generation of a tumor microenvironment that favors the proliferation, survival, and chemoresistance of cancer cells. In this review, we present the regulatory mechanisms of NRF2 and discuss how NRF2 activation contributes to chemoresistance. We also explain therapeutic strategies that exploit the vulnerabilities of NRF2-addicted cancer cells, providing NRF2 small-molecule inhibitors along with their mechanisms of action. | - |
| dc.format.extent | 30 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 대한약학회 | - |
| dc.title | NRF2 activation in cancer and overview of NRF2 small molecule inhibitors | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.1007/s12272-025-01557-x | - |
| dc.identifier.scopusid | 2-s2.0-105013332537 | - |
| dc.identifier.wosid | 001550304600001 | - |
| dc.identifier.bibliographicCitation | Archives of Pharmacal Research, v.48, no.7-8, pp 676 - 705 | - |
| dc.citation.title | Archives of Pharmacal Research | - |
| dc.citation.volume | 48 | - |
| dc.citation.number | 7-8 | - |
| dc.citation.startPage | 676 | - |
| dc.citation.endPage | 705 | - |
| dc.type.docType | Review | - |
| dc.identifier.kciid | ART003248396 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
| dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
| dc.subject.keywordPlus | ARYL-HYDROCARBON RECEPTOR | - |
| dc.subject.keywordPlus | TRANSCRIPTION FACTOR NRF2 | - |
| dc.subject.keywordPlus | LUNG-CANCER | - |
| dc.subject.keywordPlus | ANTIOXIDANT RESPONSE | - |
| dc.subject.keywordPlus | SIGNALING PATHWAY | - |
| dc.subject.keywordPlus | OXIDATIVE STRESS | - |
| dc.subject.keywordPlus | GENE-EXPRESSION | - |
| dc.subject.keywordPlus | KEAP1-NRF2 PATHWAY | - |
| dc.subject.keywordPlus | UBIQUITIN LIGASE | - |
| dc.subject.keywordPlus | RETINOIC ACID | - |
| dc.subject.keywordAuthor | Nuclear factor erythroid 2-related factor 2 (NRF2) | - |
| dc.subject.keywordAuthor | NRF2 small molecule inhibitors | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
